Alembic Pharmaceuticals Ltd (APLLTD) Q1 FY27 Earnings Call: Guides Mid-to-High Teens US Growth, Branded Business Break-Even Targeted

Alembic Pharmaceuticals Ltd held its Q1 FY27 earnings call on August 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Momentum Drives Strong Start to FY 2026-2027

• Revenue grew 26% YoY to Rs.2,150 Cr in Q1 FY 2026-2027, driven by broad-based growth across all businesses — India branded, international generics, US generics, and API.
• EBITDA rose 21% YoY to Rs.348 Cr (margin 16%), reflecting higher volumes, new launches, and better manufacturing utilization, despite planned investments in the US branded platform.
• PAT grew 12% YoY to Rs.173 Cr in Q1 FY 2026-2027, with an effective tax rate of 22% (vs. ~19% in Q1 FY 2025-2026) due to migration to the new tax regime.
• R&D spend was Rs.186 Cr (9% of revenue) in Q1 FY 2026-2027, focused on peptides, exhibit batches, and regulatory filings.
• Launched 7 products, filed 4 ANDAs, and received 10 approvals in Q1 FY 2026-2027, underscoring execution momentum.

Generics Surge 49%; Branded Platform Soft-Launched

• US generics revenue grew 49% YoY in Q1 FY 2026-2027 in reported INR terms, with a ~10% forex tailwind from rupee depreciation; constant currency growth was ~38%. Management emphasized reported rupee growth as the focus.
• Bosutinib 100 mg and 500 mg 180-day exclusivity drove a significant portion of the US outperformance; excluding Bosutinib, the US business grew approximately 20-25% in Q1 FY 2026-2027, supported by 6-7 launches in Q1 and Q4 of FY 2025-2026.
• US base business (ex-bortezomib) run-rate improved to $75-76M in Q1 FY 2026-2027 (vs. $60-65M previously), growing 25%+ YoY. Management expects this trend to continue for the next one to two quarters but cautions on potential price erosion and share loss.
• Bortezomib contributed only one month in Q1 FY 2026-2027 (launched June 2026); exclusivity secured until November 2026, supporting Q2 and part of Q3. Beyond that, sustainability is uncertain due to low volumes and potential competition.
• US branded business soft-launched in Q1 with investments in sales force and marketing only (no manufacturing capex). Management expects positive EBITDA contribution starting FY 2027-2028, with break-even targeted by Q4 FY 2026-2027 or Q1 FY 2027-2028.

Chronic Specialty at 60%; Animal Health Outperforms

• India branded business grew 7% YoY in Q1 FY 2026-2027, with animal health up 24% (22% of India revenue), driven by portfolio expansion in farm animals and poultry, field force productivity, and operational efficiency.
• Specialty business (chronic segment) comprised ~60% of total revenue in Q1 FY 2026-2027. Acute segment (37% of India revenue) is improving, with Azithral and cough/cold portfolio building traction.
• Management appointed Ramesh Juneja as Sales and Marketing Head for Human Health to strengthen execution; expects positive trends in 1-2 quarters (Q2-Q3 FY 2026-2027).
• API business grew 33% YoY in Q1 FY 2026-2027, led by volume. Management expects API growth above the initially guided ~10% level for FY 2026-2027.
• India business (excluding veterinary) guidance for FY 2026-2027 is to be closely aligned to market growth, aiming for high single-digit growth and bridging the gap from last year.

Core Margin at High Teens; Debt Targeted to ~1x EBITDA

• Core business EBITDA margin improved to high teens in Q1 FY 2026-2027 but was diluted by ~150 bps due to US branded business marketing investments. Management guided full-year ~150 bps dilution for FY 2026-2027; Q1 experienced a higher-than-150 bps impact due to the ramp-up phase.
• Gross margins remained within the guided 70-75% range in Q1 FY 2026-2027. Factors affecting gross margins: higher solvent prices due to Middle East issues, product mix, and a preventive maintenance shutdown at the Ophthal line (de-bottlenecking, no incremental capex).
• Depreciation rose sharply in Q1 FY 2026-2027, with 70-75% of the increase attributable to amortization of intangible assets acquired for the US branded business (capitalized in Q4 FY 2025-2026, amortized over 7-8 years). The company added Rs.400 Cr of capex in FY 2025-2026.
• Gross debt stood at Rs.1,600 Cr as of Q1 FY 2026-2027, higher than March 2026 levels due to increased receivables from higher sales. Management expects working capital-driven debt to unwind in Q2 and Q3 FY 2026-2027.
• Management targets reducing debt at least back to March 2026 levels and further to approximately 1x EBITDA during FY 2026-2027 (no specific quarter given). Interest cost is expected to decline in subsequent quarters as debt reduces.

Raised US Guidance; ~15 More Launches Planned

• US generics growth guidance raised for FY 2026-2027 from low-to-mid teens to mid-to-high teens (INR terms), driven by Bosutinib contribution and new launch momentum. Overall company revenue growth outlook improved to mid-teen range (from low double-digit).
• Management expects ~15 more US launches over the remaining 9 months of FY 2026-2027, with a similar number anticipated for FY 2027-2028 to offset price erosion.
• ROW business guidance: ~15% growth in INR terms for FY 2026-2027, below historical ~20% due to a high base. Management expressed confidence in achieving the guidance and expects continued growth over the next 3-4 years via Latin America, a Saudi JV, and Canada.
• For FY 2027-2028, management's goal is to grow the US business over FY 2026-2027, supported by branded business contribution starting next year, though the outlook will be clearer in the coming months.
• Reported EBITDA margins for FY 2026-2027 expected to be flat to slightly better than FY 2025-2026 (16%), depending on US branded business achieving break-even (targeted by Q4 FY 2026-2027 or Q1 FY 2027-2028). An analyst suggested assuming margins in the "high teens," which management did not correct.